Oncrasin 1 is primarily used in cancer research as a potential anticancer agent. It functions by selectively inhibiting the growth of certain tumor cells, particularly those associated with glioblastoma and other aggressive cancers. The compound targets specific signaling pathways involved in cell survival and proliferation, such as the NF-κB pathway, leading to apoptosis in cancer cells. Due to its ability to cross the blood-brain barrier, Oncrasin 1 is being investigated for use in treating brain tumors. It is also used as a molecular tool in laboratory studies to understand mechanisms of drug resistance and cancer cell death. While still in the preclinical stage, it shows promise for future development in targeted cancer therapies.